Skip to main content

Table 4 Detailed data of patients treated with preoperative TAE

From: Intended preoperative trans-arterial embolization for large hepatocellular carcinoma: a retrospective cohort study

Case Age Sex Etiology Tumor location Tumor size (mm) Frequency of TAE Time to surgery (month) Shrinkage rate (%) Necrosis rate (%) Recurrence RFS (month) Disease-specific death DSS (month)
1 63 M Alc AP 110 1 3.2 − 22.7 40 + 40 - 137
2 71 M Alc AP 150 3 7.4 − 23.3 90 + 83 - 99
3 63 M HCV AP 240 3 5.1 − 45.8 90 - 39 - 39
4 78 M HBV P 120 3 6.4 − 54.2 100 - 25 - 25
5 65 M Alc PA 110 2 11.9 − 7.4 100 - 9 - 9
  1. Tumor size is pre-TAE value
  2. TAE trans-arterial embolization, M male, Alc alcoholic hepatitis, HCV hepatitis C virus-induced hepatitis, HBV hepatitis B virus-induced hepatitis, A anterior segment, P posterior segment, RFS recurrence-free survival, DSS disease-specific survival